Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bellicum Pharmaceuticals Inc | BLCM | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.25 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.25 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.15 - 1.31 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.25 | USD |
Bellicum Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 2.43M | - | - | - | -0.11 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Bellicum Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/23/2024 | 12:19 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration.. |
| 2/23/2024 | 12:17 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
| 2/14/2024 | 17:00 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 2/14/2024 | 13:23 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial.. |
| 1/30/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 1/24/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BLCM Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 0.37 | 1.31 | 0.15 | 0.9078806 | 5,160,985 | -0.12 | -32.43% |
| 3 Years | 3.54 | 4.04 | 0.15 | 1.13 | 438,302 | -3.29 | -92.94% |
| 5 Years | 3.13 | 12.15 | 0.15 | 1.92 | 478,665 | -2.88 | -92.01% |
Bellicum Pharmaceuticals Description
| Bellicum Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. Its research areas are cellular immunotherapies for hematological cancers, solid tumors, and orphan inherited blood diseases. The company's expertise is based on the inclusion of powerful molecular switches planned to eliminate, reduce, or activate therapeutic cells to increase efficacy and safety compared with existing cell therapies. Its pipeline portfolio includes adjunct T-cell therapy to treat leukemias, lymphomas, and genetic blood diseases; CAR T cells technology to treat prostate, pancreatic, bladder, esophagus, and gastric cancers; and BCMA GoCAR-NK the program targeting B-cell maturation antigen. |
